Results 191 to 200 of about 2,932,876 (332)
The Diagnostic Value of Visual Evoked Potentials in Chronic Disorders of Consciousness
ABSTRACT Objective In chronic disorders of consciousness (DOCs), the distinction between vegetative state/unresponsive wakefulness syndrome (VS/UWS) and minimally conscious state (MCS) is as crucial as it is challenging. Evoked potentials (EPs) and event‐related potentials (ERPs) are helpful, but some limitations prevent their consistent use in the ...
Letizia Clementi+14 more
wiley +1 more source
Demonstrating library value: the development of a customizable Library Value Planner. [PDF]
Mueller M+4 more
europepmc +1 more source
Descriptive Catalogue of Hebrew MSS. of the Montefiore Library [PDF]
Hartwig Hirschfeld
openalex +1 more source
ABSTRACT Objective Reliable biomarkers are essential for tracking disease progression and advancing treatments for multiple system atrophy (MSA). In this study, we propose the MSA Atrophy Index (MSA‐AI), a novel composite volumetric measure to distinguish MSA from related disorders and monitor disease progression. Methods Seventeen participants with an
Paula Trujillo+11 more
wiley +1 more source
A Benchmark Set of Bioactive Molecules for Diversity Analysis of Compound Libraries and Combinatorial Chemical Spaces. [PDF]
Neumann A, Klein R.
europepmc +1 more source
Catalogue of Persian Manuscripts in the Library of the India Office, volume 1 [PDF]
Hermann Ethé
openalex +1 more source
ABSTRACT Objective Malignant gliomas pose significant therapeutic challenges. This study aimed to identify and characterize a novel chimeric RNA in glioma and assess its clinical and functional significance for precision treatment. Methods The C19orf47‐AKT2 chimeric RNAs were identified through RNA sequencing and validated by polymerase chain reaction.
Zihan Wang+11 more
wiley +1 more source
Guidelines in the Preparation of Fully Synthetic, Human Single-Domain Antibody Phage Display Libraries. [PDF]
Tornetta MA+6 more
europepmc +1 more source
Durable B‐Cell Impairment While Sparing IgA B Cells After Ocrelizumab Therapy in Multiple Sclerosis
ABSTRACT Objectives Ocrelizumab (OCR), a humanized anti‐CD20 monoclonal antibody, is highly efficient in relapsing–remitting multiple sclerosis (RR‐MS). We assessed early cellular B‐cell profiles in patients prior to OCR treatment, on OCR treatment, and after 15 months of therapy discontinuation.
Alexandra Garcia+20 more
wiley +1 more source